CMS Blocks All New Medical Supply Companies While Existing Fraudsters Keep Billing

Summary

• The claim is largely inaccurate: the full Federal Register notice and supporting documents contain substantial fraud evidence, including dollar amounts, revocation rates, case examples, and multi-year OIG data — the article excerpt provided was simply incomplete.
• The single most concrete data point: medical supply companies have a 17% Medicare billing privileges revocation rate, nearly three times the ~6% rate for other DMEPOS types, directly justifying the targeted moratorium.
• Dollar amounts are significant and specific: CMS stopped over $1.5 billion in suspected fraudulent DMEPOS billing in 2025, and the OIG has documented 'billions of dollars' in potentially improper Medicare payments to DME suppliers over more than a decade.
• The article's excerpt cuts off before the 'Medicare Data Analysis' section, which the notice explicitly states contains detailed enrollment, claims, and fraud indicator data across 80+ DMEPOS supplier types — the missing evidence exists in the full document.
• The moratorium is narrowly scoped to seven specific medical supply company subtypes and was announced alongside $5.7 billion in suspended Medicare payments in 2025, indicating a data-driven rather than arbitrary enforcement action.

Assessment: The Claim is Largely Inaccurate

The assertion that the article provides "no concrete evidence — no fraud statistics, case examples, dollar amounts, or geographic hotspots" is not fully accurate. While the pasted excerpt of the article is incomplete (it cuts off mid-sentence), the full Federal Register notice and its supporting documentation contain substantial, specific evidence justifying the moratorium. The claim mischaracterizes the notice as evidence-free when, in fact, significant quantitative and qualitative data underpins it.

What Specific Fraud Evidence Was Cited?

Quantitative Data in the Record:

The most striking statistic is the 17% revocation rate for medical supply companies, compared to approximately 6% for other DMEPOS supplier types — nearly three times the baseline rate for the broader category. This is a direct, data-driven indicator of disproportionate fraud and abuse concentrated in this specific supplier type, and it forms a core part of CMS's analytical justification.

Beyond revocation rates, CMS analyzed indicators across more than 80 types of DMEPOS suppliers in the Medicare FFS program, examining percentages of suppliers with revocations of billing privileges, payment suspensions based on credible fraud allegations, law enforcement referrals, investigations, and benefit integrity unit (BIU) complaints since 2023.

Dollar Amounts Are Substantial:

- CMS stopped more than $1.5 billion in suspected fraudulent DMEPOS billing in 2025 alone. - CMS suspended $5.7 billion in suspected fraudulent Medicare payments in 2025 overall, with $3.7 billion in billing referred to law enforcement. - The OIG, as recently as February 2025, explicitly stated it has "highlighted billions of dollars in potentially improper Medicare payments" to DME suppliers over more than a decade of concern.

Case Examples and Patterns:

The OIG and DOJ have been actively investigating and charging DMEPOS supplier owners nationwide for fraudulent billing schemes. One documented case involved a company producing and selling medical inserts while "cutting corners" to increase profits — a patient harm example, not merely a billing irregularity. The OIG has also documented that fraud, waste, and abuse by DMEPOS suppliers results in patient harm, including beneficiaries receiving unnecessary or substandard items.

Historical and Institutional Context:

OIG reports on DMEPOS payment safeguard issues date back to 1998, and fraudulent billing for DMEPOS was explicitly described in 2024 as "a major concern" despite CMS having multiple existing safeguards in place. DMEPOS suppliers are required to revalidate every three years, yet longstanding fraud has persisted through these requirements.

Why the Claim Has Some Partial Merit

The article excerpt provided to the user does cut off before the "Medicare Data Analysis" section, which the notice itself references as containing detailed enrollment and claims data. The excerpt also does not include the full OIG discussion promised in "section II." So a reader seeing only the truncated text might reasonably feel the quantitative evidence was missing — but this reflects the incompleteness of the excerpt, not an absence of evidence in the underlying document.

Additionally, the moratorium targets seven specific supplier subtypes (those with orthotics personnel, pedorthic personnel, prosthetics personnel, prosthetic and orthotic personnel, registered pharmacist, and respiratory therapist designations), which reflects a targeted, data-informed scope rather than a blanket, unjustified action.

Political Context

The moratorium was announced on February 25, 2026, by Vice President J.D. Vance, HHS Secretary Robert F. Kennedy Jr., and CMS Administrator Dr. Mehmet Oz as part of a coordinated anti-fraud initiative. This high-profile rollout suggests the action was accompanied by public-facing evidence and messaging beyond what appears in the regulatory notice excerpt alone.

Summary

• The 17% revocation rate claim is CONFIRMED and well-supported: CMS's own Medicare enrollment data (2023–October 2025) documents a ~17% revocation rate for medical supply company specialties, compared to ~6% for other DMEPOS types — making the 'nearly triple' characterization accurate (≈2.83x).
• The fact-check critique's concern about the missing baseline comparison is RESOLVED by supplementary sourcing, which explicitly quantifies the ~6% rate for other DMEPOS supplier types, enabling direct verification of the 'triple' claim.
• The 'eventually had' vagueness is PARTIALLY RESOLVED: the revocation rate was measured over a defined window (2023 through late October 2025), not an open-ended historical period — though the article's phrasing obscures this specificity.
• The revocation rate is corroborated by a consistent pattern of elevated fraud indicators across multiple independent metrics: medical supply companies also had higher payment suspension rates, law enforcement referral rates, and BIU complaint rates than other DMEPOS types during the same period.
• The critique's concern about trend direction (increasing/stable/declining) remains the one UNRESOLVED gap — no available source provides time-series data showing whether the 17% rate is worsening or improving, though OIG has flagged DME fraud concerns for over a decade.

Assessment of the 17% Revocation Rate Claim

The core claim — that medical supply company specialties had a 17 percent revocation rate, nearly triple the rate for other DMEPOS supplier types — is well-supported by the primary source document and corroborated by supplementary data. The fact-check critique raises legitimate methodological concerns, but several of those concerns can now be addressed with the available evidence.

---

What the Evidence Shows

The 17% figure is confirmed. The Federal Register notice (the article itself, Source 1) directly states that medical supply company specialties had a 17 percent revocation rate from 2023 to October 2025. This is not a vague or unsourced claim — it comes from CMS's own Medicare enrollment and claims data analysis, which reviewed more than 80 types of DMEPOS suppliers.

The "triple the rate" comparison is now quantifiable. The fact-check critique noted that the document does not specify the revocation rate for "other types," making the "triple" comparison difficult to independently verify. However, supplementary sourcing resolves this: the rate for other DMEPOS supplier types is approximately 6 percent, versus approximately 17 percent for medical supply companies. This confirms that the "nearly triple" characterization is accurate (17% ÷ 6% ≈ 2.83x, i.e., nearly triple).

The "eventually had" vagueness is partially resolved. The article's phrasing is indeed imprecise, but the underlying data clarifies the timeframe: the revocation rate was measured from 2023 through late October 2025 — a defined ~2.5-year window. This is not an open-ended historical accumulation; it is a bounded measurement period, which makes the figure more precise than the phrase "eventually had" implies.

---

The Revocation Rate in Broader Context

The 17% revocation rate does not stand alone — it is part of a consistent pattern of elevated fraud indicators across multiple metrics for medical supply companies:

- Higher payment suspension rates compared to other DMEPOS supplier types from 2023 through late October 2025 - Higher law enforcement referral rates during the same period - Higher BIU (Benefit Integrity Unit) complaint rates during the same period

This convergence across multiple independent fraud indicators strengthens the credibility of the revocation rate figure — it is not an outlier statistic but part of a coherent pattern.

The financial scale of the problem further contextualizes the urgency. CMS suspended $5.7 billion in suspected fraudulent Medicare payments in 2025, with $1.5 billion of that attributable specifically to suspected fraudulent DMEPOS billing. In July 2025, eleven defendants were indicted in a scheme that submitted over $10.6 billion in fraudulent Medicare claims for DME.

---

What the Critique Gets Right

The fact-check critique's concern about trend data remains valid and unresolved by available sources. The 2023–October 2025 window tells us the rate during that period, but no source in the provided set shows whether the 17% rate is increasing, stable, or declining over time. The OIG noted in February 2025 that it had raised concerns about DME supplier fraud for over a decade, suggesting this is a persistent rather than newly emerging problem — but that does not confirm whether the rate is worsening.

The critique's concern about the baseline comparison has been substantially addressed by the ~6% figure for other DMEPOS types.

---

Structural Context of the Moratorium

Medical supply companies comprise approximately 6,000 suppliers, representing roughly 7.5 percent of the ~80,000+ total DMEPOS suppliers enrolled in Medicare. Despite being a relatively small share of total suppliers, their disproportionate fraud indicators — including the 17% revocation rate — drove CMS to implement a six-month nationwide moratorium on new Medicare enrollment for this category, announced February 25, 2026, and published in the Federal Register on February 27, 2026.

Summary

• The 70% and 80% figures are drawn from a defined CMS dataset (CY 2023–late October 2025) with explicitly stated claim volumes (2.1M and 1.5M lines), making them internally anchored — not percentages without any denominator.
• The critique's methodological point is valid: without knowing medical supply companies' overall share of all DMEPOS claims, readers cannot confirm these figures represent disproportionate concentration rather than a natural market baseline.
• However, the missing denominator is less critical here because CMS is measuring concentration within a specific, pre-identified high-fraud-risk category (32 Master List brace codes), not making a general market-share claim.
• Independent OIG audits and reports — spanning over a decade — corroborate the fraud risk in this exact supplier-product combination, including $4 billion in orthotic brace payments during 2016–2018 with some suppliers receiving 90%+ unallowable payments.
• The figures are best characterized as accurate and contextually meaningful, though CMS could have strengthened transparency by publishing comparative revocation and fraud referral rates by supplier type within the brace category.

Assessment of the Claim

The critique raised is analytically valid: the article presents 70% and 80% concentration figures for medical supply companies' share of prefabricated orthotic brace claims without explicitly stating what share of all DMEPOS claims medical supply companies submit overall. However, a careful reading of the available evidence suggests this omission is less misleading than the critique implies, and the figures remain meaningful in context.

What the Article Actually States

The article reports two specific, internally consistent data points drawn from CMS billing data covering CY 2023 through late October 2025:

- Medical supply companies submitted more than 70% of the 2.1 million claim lines for the 32 prefabricated orthotic brace codes on the Master List. - For the most problematic subcategory — off-the-shelf (OTS) braces — medical supply companies submitted more than 80% of the 1.5 million claim lines.

These figures are drawn from a defined, bounded dataset: specifically the 32 prefabricated brace codes flagged on the Master List as susceptible to fraud, waste, and abuse. The claim volumes (2.1M and 1.5M lines) are themselves meaningful anchors — they are not percentages floating without a denominator, but rather percentages of a stated total claim line count.

Is the Missing Denominator a Fatal Flaw?

The critique correctly identifies that without knowing what share of all DMEPOS claims medical supply companies submit, a reader cannot determine whether 70–80% concentration is disproportionate or simply reflects the natural market composition of the DMEPOS supplier landscape.

However, several contextual factors limit the force of this objection:

1. The comparison class is intentional. CMS is not comparing medical supply companies to all DMEPOS suppliers across all product categories. The moratorium is specifically targeted at medical supply companies submitting claims for prefabricated orthotic braces — a narrowly defined, high-fraud-risk category. The 70–80% figures describe concentration within that specific risk category, not the broader DMEPOS universe.

2. The OIG's longstanding findings provide independent corroboration. The OIG stated in February 2025 that "for over a decade, OIG has raised concerns about fraudulent practices among DME suppliers and has highlighted billions of dollars in potentially improper Medicare payments." This is not a new or isolated data point — it reflects a sustained pattern of enforcement concern.

3. Audit findings confirm disproportionate improper payments. From July 2016 through December 2018 alone, Medicare paid approximately $4 billion for orthotic braces, and orthotic braces ranked among the top 20 DMEPOS items with the highest improper payment rates during that audit period. Individual audits found that Freedom Orthotics, Inc. received at least $6.9 million in unallowable payments out of $7.7 million billed, and Kelley Medical Equipment and Supply received at least $4 million in unallowable payments. These are not marginal error rates.

4. The OTS subcategory is specifically flagged. Nine of the 32 prefabricated braces fall into the OTS category, and a dedicated 2024 OIG report (A-09-21-03019) specifically highlighted OTS orthotics as a major fraud, waste, and abuse risk. The 80%+ concentration figure for OTS braces thus aligns with a separately established risk profile.

What Would Strengthen the Analysis

The critique is fair as a matter of analytical completeness. To fully evaluate whether medical supply companies are overrepresented in high-risk brace billing, CMS could have disclosed:

- The total share of all DMEPOS claim lines submitted by medical supply companies (vs. other supplier types such as orthotists, prosthetists, or pharmacies). - A breakdown of revocation rates, payment suspensions, and fraud referrals by supplier type within the brace category specifically.

The article does note that CMS analyzed "the percentages of DMEPOS suppliers within each type that had a revocation of Medicare billing privileges, payment suspension based on a credible allegation of fraud or reliable indication that an overpayment exists, law enforcement referral, investigation, or benefit integrity unit (BIU) complaint since 2023," but does not publish those comparative figures in the excerpted text.

Bottom Line

The 70% and 80% figures are not fabricated or unsupported — they are drawn from a defined CMS dataset with stated claim volumes. The critique's point about the missing denominator is methodologically sound but does not undermine the core finding, given the extensive independent OIG and audit evidence of disproportionate fraud in this specific supplier-product combination. The figures are best understood as describing concentration within a high-risk category, not as a standalone proof of disproportionality across all DMEPOS billing.